CHRO fundamentals
An in-depth look to Chromocell Therapeutics Corporation operating, investing, and financing activities
CHRO free cash flow for Q1 24 is -1.99 M USD. For 2023, CHRO free cash flow was -981.03 k USD and operating cash flow was -981.03 k USD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM